Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab-deruxtecan for HER2-positive Oligo-metastatic Breast Cancer
NCT05982678Phase 2Recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- May 2024
- Primary completion
- Oct 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab deruxtecan in breast cancer, sponsored by Netherlands Cancer Institute. Primary endpoint: Complete radiologic response at 1 year. Started May 2024; status: recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05982678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05982678.